Chapter 4 of 25
- A high-risk HPV infection may persist
- Viral effects can disrupt normal cell controls
- A minority of infections eventually contribute to oropharyngeal cancer
- Testing, staging and appropriate treatment remain necessary
What HPV is
Human papillomavirus, or HPV, is a large family of viruses. Many infections cause no lasting problem and are controlled by the immune system. Certain high-risk types can persist and affect normal controls on cell growth. HPV16 is particularly important in HPV-associated oropharyngeal cancer, usually arising in a tonsil or the base of the tongue.
The process from infection to cancer can take many years. Most people with HPV never develop cancer. An HPV-related cancer does not establish when an infection began, identify a partner as its source or imply recent infidelity. It is not a reason for blame or separation.
Why the biology is different
HPV-associated tumours arise through viral effects on cell-regulating pathways. Tobacco-associated tumours usually develop through other patterns of genetic damage. A person can have HPV-associated cancer and also have smoked; the categories do not describe every part of their history.
On average, appropriately treated HPV-associated oropharyngeal cancers have a more favourable outlook than HPV-negative cancers of the same region. Individual prognosis still depends on the extent of disease, tobacco history, general health and response to treatment. The statement is not a promise of cure and does not mean that a large neck node can be ignored.
Understanding p16 and HPV-specific tests
p16 immunohistochemistry is a laboratory stain performed on tumour tissue. It detects a protein whose strong staining pattern can act as a surrogate marker for HPV association in the appropriate oropharyngeal setting. “Surrogate” means a useful indirect marker, not the virus itself. HPV-specific tests detect viral material through methods such as in-situ hybridisation or molecular testing.
The 2025 College of American Pathologists guideline provides site- and specimen-specific testing recommendations. p16 alone is insufficient in some situations, including discordant morphology or clinical context. Testing of a lymph-node needle sample also requires an appropriate validated approach. The pathologist decides whether additional HPV-specific testing is needed.
A p16-positive result in a cancer outside the oropharynx should not automatically be interpreted as HPV-driven disease with the same prognosis. Ask: “Was this test appropriate for my cancer site, and does the final report establish HPV association?” Keep the original report rather than relying only on a verbal description of “HPV positive”.
Staging and treatment implications
HPV-associated oropharyngeal cancer uses a distinct staging system. This guide identifies the applicable AJCC edition by site; AJCC Version 9 for HPV-associated oropharynx became effective in 2026. An old trial’s stage label may therefore not mean the same thing as a current report’s stage label. The oncology team should interpret both the anatomical burden and the version used.
Treatment can include radiation, systemic treatment and/or selected surgery. Choice depends on the individual disease pattern and likely speech and swallowing outcomes. A favourable prognosis does not automatically make lower-dose radiation, omission of chemotherapy or replacement of cisplatin safe. De-escalation means intentionally reducing treatment intensity; it should follow an evidence-supported pathway or clinical trial rather than be assumed appropriate from HPV status alone.
Vaccination and prevention
HPV vaccination helps prevent infections by covered HPV types. It works best before exposure but eligibility and catch-up policies vary by country, age and circumstances. Ask about the locally recommended vaccine and schedule for children and eligible adults. The vaccine prevents future infection-related disease; it does not treat an established tumour or clear a proven cancer.
Vaccination does not remove the need for recommended cervical screening for people with a cervix. Avoiding tobacco remains valuable regardless of HPV status. Barrier protection may reduce exposure during sexual activity but cannot completely prevent HPV transmission because uncovered skin can also transmit the virus.
Partners, families and everyday contact
There is no established routine screening test for HPV-related throat cancer in an asymptomatic general population. Partners do not usually need an oral HPV test simply because someone has an HPV-associated tumour. They should follow ordinary preventive care, vaccination advice and any appropriate cervical screening programme. Persistent symptoms still require assessment.
Cancer itself is not contagious. Sharing a home, hugging and offering routine care do not spread a person’s cancer. Sexual-health questions can be discussed privately with the team, including any temporary precautions related to treatment. A diagnosis alone does not require abandoning intimacy or routine family affection. If anxiety or relationship conflict develops, a counsellor or sexual-health professional can help explain the uncertainty without assigning blame.
References and evidence review
- College of American Pathologists: HPV Testing in Head and Neck Carcinomas, guideline update (2025)
- NCI: HPV and Cancer (2025)
- WHO: Human papillomavirus and cancer (2024)
- American College of Surgeons: AJCC Current Staging System (2026)
- NCI PDQ: Oropharyngeal Cancer Treatment (2025)
Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.